Nebulized dexmedetomidine for early chronic migraine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will administer nebulized dexmedetomidine to adults with early chronic migraine, defined as 15 or more headache days per month for at least 3 months with migraine features on most days. The goal is to see if the treatment reduces central sensitization in the trigeminovascular system, potentially lowering pain intensity and frequency. The approach relies on the central antinociceptive effects of dexmedetomidine delivered via inhalation to achieve rapid CNS exposure with minimal sedation. Participants must not have recent preventive therapy or conflicting comorbidities, and will be evaluated for changes in migraine activity and associated sensitization markers. The sponsor is Beni-Suef University, and the study is conducted at Beni-Suef University Hospital in Banī Suwayf, Egypt.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Early chronic migraine (\<6 months of ≥15 headache days/month), per ICHD-3 criteria.
* No preventive migraine therapy in the prior 8 weeks.

Exclusion Criteria:

* Presence of cardiopulmonary, psychiatric, or neurological comorbidities.
* Current use of sedatives, opioids, or CGRP-targeting therapies.
* Pregnancy or breastfeeding.

Where it's running

• Beni-Suef University Hospital
  Banī Suwayf, Egypt Recruiting

Study contacts

• Study coordinator: Ibthal Osama Fathy Ibrahim, MSc
• Email: Ibthal21@gmail.com
• Phone: +201098273360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• i-NEED: New migraine drugs database

  This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.

  Recruiting at 2 sites IRCCS San Raffaele Roma · Milan, Italy and 1 other locations · NCT07103694

• Suppressive Functions of Regulatory T Cells in Migraine

  This study tests whether regulatory T cells can help control migraine-related inflammation in adults with chronic migraine.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07067112

• Comparing sphenopalatine block and BOTOX for chronic migraine relief

  This study is testing whether a nerve block or BOTOX injections can help people with chronic migraines feel better.

  Recruiting Cairo University · Cairo · NCT06974617

• Using Atogepant tablets to prevent migraines in teens aged 12 to 17

  This study is testing if Atogepant tablets can help prevent migraines in teenagers aged 12 to 17.

  Recruiting at 61 sites Phase 3 AbbVie · Huntsville, Alabama and 65 other locations · NCT06810505

• Acceptance and Commitment Therapy to reduce disability in adults with chronic migraine

  This trial will test whether adding Acceptance and Commitment Therapy (ACT) to usual care helps adults with chronic migraine improve daily functioning and reduce headache frequency and pain.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06795867

• Comparing nerve block injections to Botox for chronic migraine relief

  This study tests whether nerve block injections or Botox can help adults with chronic migraines feel better and have fewer migraine days.

  Recruiting Zagazig University · Zagazig, Sharqia Province · NCT06684249

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.